Nestlé ups its bet on Aimmune’s peanut allergy drug to $276M as NDA filing looms, rivalry intensifies

Nestlé Health Science is upping its bet on Aimmune Therapeutics by $98 million $AIMT, with its now $276 million stake in the company giving it 19% of the biotech’s equity.